CTOs on the Move

Nutra Manufacturing

www.nutramfg.com

 
Nutra Manufacturing, Inc is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.nutramfg.com
  • 1050 Woodruff Rd
    Greenville, SC USA 29607
  • Phone: 864.297.1400

Executives

Name Title Contact Details

Similar Companies

Kenney Orthopedics

Restoring Motion – Empowering Lives. Kenney Orthopedics, LLC, is committed to providing quality orthopedic and prosthetic related products and services.

SourceMark

A certified minority-owned business, SourceMark continues to focus on your needs to improve the lives of all patients, customers, and healthcare providers. Our clinical advisory groups are personally involved with the continued improvement of current p...

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company focused on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases. Our therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.